Fifty patients with acute coronary syndrome (ACS) and at least one lesion with <sup>18</sup> FDG uptake in the carotid artery (target-to-background ratio [TBR] ≥ 1.6) were randomly assigned to receive either fimasartan (60 mg once a day) or amlodipine (5 mg once a day).
In this 2-by-2 factorial trial, 50 patients with <sup>18</sup>FDG uptake (target-to-background ratio [TBR] ≥1.6) in the carotid artery and acute coronary syndrome were randomized to receive either simvastatin/ezetimibe 10/10 mg or rosuvastatin 10 mg. <sup>18</sup>FDG PET/CT examinations were performed at baseline and at 6 months.